Phase III SENTRY And XPOVIO Approvals Will Secure Future Success

AN
AnalystConsensusTarget
Consensus Narrative from 6 Analysts
Published
08 Apr 25
Updated
24 Jul 25
AnalystConsensusTarget's Fair Value
US$29.25
86.7% undervalued intrinsic discount
24 Jul
US$3.88
Loading
1Y
-69.2%
7D
-6.1%

Author's Valuation

US$29.3

86.7% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on01 May 25
Fair value Decreased 35%

Shared on24 Apr 25
Fair value Increased 54%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25
Fair value Decreased 1.10%